High-dose MTX as CNS prophylaxis safe, feasible in non-Hodgkin lymphoma patients
An ambulatory high-dose methotrexate (MTX) regimen administered as central nervous system (CNS) prophylaxis in patients with non-Hodgkin lymphoma appears to be safe and feasible, a study has shown.
High-dose MTX as CNS prophylaxis safe, feasible in non-Hodgkin lymphoma patients
20 May 2020
